Profile data is unavailable for this security.
About the company
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
- Revenue in USD (TTM)2.86m
- Net income in USD-3.16m
- Incorporated2011
- Employees2.00
- LocationXenetic Biosciences Inc945 Concord St.FRAMINGHAM 01701United StatesUSA
- Phone+1 (781) 778-7720
- Websitehttps://www.xeneticbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Green Med Solution Inc | 81.00k | -6.97m | 4.70m | 12.00 | -- | 0.4734 | -- | 58.08 | -80.13 | -80.13 | 0.0775 | 2.03 | 0.012 | -- | 0.0821 | -- | -80.35 | -65.34 | -175.85 | -83.85 | 20.99 | -- | -6,714.82 | -17,774.73 | 5.07 | -241.39 | 0.00 | -- | -89.76 | -- | 50.73 | -- | -- | -- |
| Nymox Pharmaceutical Corp | -100.00bn | -100.00bn | 4.79m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0717 | -- | -- | -- | -- | -- | -397.74 | -- | -- | -- | -- | -- | -883,740.00 | -- | -- | -- | -- | -- | -- | 49.21 | -- | -- | -- |
| MetaVia Inc | 0.00 | -16.22m | 5.00m | 9.00 | -- | 0.5424 | -- | -- | -13.88 | -13.88 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -87.87 | -99.54 | -167.49 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| VivoSim Labs Inc | 142.00k | -1.23m | 5.01m | 5.00 | 1.80 | 1.13 | -- | 35.26 | 1.07 | 1.07 | 0.0608 | 1.70 | 0.0263 | -- | 4.81 | 10,923.08 | -22.71 | -51.63 | -45.51 | -56.47 | 100.00 | -- | -864.08 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 5.10m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 5.10m | -- | -- | 0.7999 | -- | 70.73 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 2.86m | -2.20m | 5.30m | 1.00 | -- | 0.523 | -- | 1.86 | -0.7587 | -0.7587 | 1.00 | 2.58 | 0.2957 | -- | 39.65 | 2,855,000.00 | -22.77 | -53.70 | -24.80 | -63.57 | -- | -- | -77.02 | -1,913.83 | -- | -- | 0.00 | -- | -- | -15.00 | 75.72 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 5.30m | 36.00 | -- | 4.90 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 5.34m | 2.00 | -- | 0.9087 | -- | 1.87 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.45m | 28.00 | -- | 0.7596 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -9.25m | 5.54m | 11.00 | -- | 0.7449 | -- | -- | -25.21 | -25.21 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -125.80 | -- | -221.96 | -- | -- | -- | -- | -- | -- | -84.50 | 0.1808 | -- | -- | -- | -223.39 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -12.93m | 5.76m | 10.00 | -- | 0.9207 | -- | -- | -35.00 | -35.00 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -206.50 | -104.23 | -270.68 | -112.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -- | -- |
| StimCell Enegetics Inc | 0.00 | -935.22k | 5.87m | 0.00 | -- | -- | -- | -- | -0.0461 | -0.0461 | 0.00 | -0.0738 | 0.00 | -- | -- | -- | -2,062.23 | -844.03 | -- | -- | -- | -- | -- | -18,037.46 | -- | -17.22 | -- | -- | -- | -- | -297.42 | -- | -- | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 5.94m | 8.00 | -- | 0.4652 | -- | 12.16 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| BioNexus Gene Lab Corp | 9.47m | -2.30m | 5.98m | 30.00 | -- | 0.6669 | -- | 0.6319 | -1.28 | -1.28 | 5.27 | 3.79 | 1.02 | 6.73 | 6.42 | -- | -24.68 | -6.00 | -27.80 | -7.75 | 14.77 | 14.31 | -24.27 | -4.98 | 6.81 | -1,354.05 | 0.00 | -- | -2.66 | 137.09 | 39.20 | -- | 77.67 | -- |
Data as of Mar 04 2026. Currency figures normalised to Xenetic Biosciences Inc's reporting currency: US Dollar USD
9.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2025 | 178.51k | 7.79% |
| Citadel Securities LLCas of 31 Dec 2025 | 14.88k | 0.65% |
| DRW Securities LLCas of 31 Dec 2025 | 13.82k | 0.60% |
| Geode Capital Management LLCas of 31 Dec 2025 | 13.58k | 0.59% |
| Tower Research Capital LLCas of 31 Dec 2025 | 4.01k | 0.18% |
| JTC Plc /Private Banking/as of 31 Dec 2025 | 2.70k | 0.12% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 1.24k | 0.05% |
| Alexis Investment Partners LLCas of 31 Dec 2025 | 25.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 17.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 3.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
